公开(公告)号：US20240285610A1

公开(公告)日：2024-08-29

申请号：US18649759

申请日：2024-04-29

申请人： Fertin Pharma A/S

发明人： Bruno Provstgaard Nielsen ,  Kent Albin Nielsen

IPC分类号： A61K31/465 ,  A61K9/00 ,  A61K9/20 ,  A61P25/34

CPC分类号： A61K31/465 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/2095 ,  A61P25/34

摘要： The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.

公开(公告)号：US20240115518A1

公开(公告)日：2024-04-11

申请号：US18520444

申请日：2023-11-27

申请人： PACIFIC UNIVERSITY

发明人： John P. Harrelson ,  Deepa A. Rao

IPC分类号： A61K31/11 ,  A61K9/00 ,  A61K31/465 ,  A61P25/34

CPC分类号： A61K31/11 ,  A61K9/0053 ,  A61K31/465 ,  A61P25/34

摘要： Compounds, compositions, and methods of use of such compounds and compositions are provided for reducing human dependency to nicotine. In one example, a method of treating an individual with an addiction to nicotine comprises administering to the individual a compound that is a structural analog of trans-cinnamaldehyde. Based on the administration, a rate at which nicotine is metabolized may be reduced, which in turn may reduce a desire for the individual to consume nicotine-containing products.

公开(公告)号：US11865156B2

公开(公告)日：2024-01-09

申请号：US17474952

申请日：2021-09-14

申请人： NFL Biosciences

发明人： Bruno Lafont

IPC分类号： A61K36/81 ,  A61K9/00 ,  A61K9/19 ,  A61P25/34 ,  A61P25/36

CPC分类号： A61K36/81 ,  A61K9/0019 ,  A61K9/19 ,  A61P25/34 ,  A61P25/36 ,  A61K2236/15 ,  A61K2236/51 ,  A61K2236/53

摘要： The invention relates to a tobacco leaf extract containing, relative to the total weight of the extract, at least 5 wt.-% proteins essentially free of molecules with a molecular mass of less than 10 kDa. The invention also relates to a pharmaceutical composition containing such an extract and to the use thereof in the treatment of tobacco addiction.

公开(公告)号：US20230346768A1

公开(公告)日：2023-11-02

申请号：US18348891

申请日：2023-07-07

申请人： Fertin Pharma A/S

发明人： Bruno Provstgaard Nielsen ,  Kent Albin Nielsen

IPC分类号： A61K31/465 ,  A61K9/00 ,  A61K9/20 ,  A61P25/34

CPC分类号： A61K31/465 ,  A61K9/0056 ,  A61K9/2009 ,  A61P25/34 ,  A61K9/006 ,  A61K9/2027 ,  A61K9/2095

摘要： The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.

公开(公告)号：US20240325317A1

公开(公告)日：2024-10-03

申请号：US18737889

申请日：2024-06-07

申请人： PACIFIC UNIVERSITY

发明人： John P. Harrelson ,  Deepa A. Rao

IPC分类号： A61K31/11 ,  A61K9/00 ,  A61K31/465 ,  A61P25/34

CPC分类号： A61K31/11 ,  A61K9/0053 ,  A61K31/465 ,  A61P25/34

摘要： Compounds, compositions, and methods of use of such compounds and compositions are provided for reducing human dependency to nicotine. In one example, a method of treating an individual with an addiction to nicotine comprises administering to the individual a compound that is a structural analog of trans-cinnamaldehyde ((2E)-3-Phenylprop-2-enal):




Based on the administration, a rate at which nicotine is metabolized may be reduced, which in turn may reduce a desire for the individual to consume nicotine-containing products.

公开(公告)号：US12084437B2

公开(公告)日：2024-09-10

申请号：US17868856

申请日：2022-07-20

申请人： AstraZeneca AB ,  EOLAS THERAPEUTICS, INC.

发明人： Theodore M. Kamenecka ,  Jörg Holenz ,  Steven Wesolowski ,  Yuanjun He ,  Roland Bürli

IPC分类号： A61K31/506 ,  A61P25/34 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

CPC分类号： C07D417/14 ,  A61P25/34 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

摘要： The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

公开(公告)号：US20240252480A1

公开(公告)日：2024-08-01

申请号：US18565558

申请日：2022-06-01

申请人： GlaxoSmithKline Consumer Healthcare Holdings {US) LLC

发明人： Jacqueline Anne ERICKSON ,  Muralikrishnan ANGAMUTHU ,  Gary John FAGAN ,  Satish Vasudev KAMATH

IPC分类号： A61K31/465 ,  A61K9/00 ,  A61K9/20 ,  A61K47/58 ,  A61P25/34

CPC分类号： A61K31/465 ,  A61K9/0056 ,  A61K9/2086 ,  A61K9/2095 ,  A61K47/585 ,  A61P25/34

摘要： A novel dosage form for intra-oral delivery of nicotine for use in nicotine replacement therapy; a process for preparation of said dosage form and intermediate compositions therefor; and methods for treatment.

公开(公告)号：US11931326B2

公开(公告)日：2024-03-19

申请号：US17861054

申请日：2022-07-08

申请人： DIET SHIELD LTD

发明人： Andrew Kitchner ,  Denis Carr

IPC分类号： A01N37/00 ,  A01N25/00 ,  A01N37/12 ,  A01N37/44 ,  A61K9/00 ,  A61K31/16 ,  A61K31/164 ,  A61K31/165 ,  A61K31/215 ,  A61K31/24 ,  A61K47/10 ,  A61K47/44 ,  A61P3/04 ,  A61P25/34

CPC分类号： A61K31/164 ,  A61K9/0014 ,  A61K31/16 ,  A61K31/165 ,  A61K47/10 ,  A61K47/44 ,  A61P3/04 ,  A61P25/34

摘要： Provided are compositions and methods comprising a sanshool for the treatment of obesity as part of a controlled diet regime in an individual. Also provided are compositions and methods comprising a sanshool for treatment of a smoking or vaping addiction. Suitably the compositions are applied topically to the lips of the individual in response to a habitual urge to consume food, smoke or vape as required.

公开(公告)号：US20170027972A1

公开(公告)日：2017-02-02

申请号：US15178138

申请日：2016-06-09

申请人： The Royal Institution for the Advancement of Learning / McGill University

发明人： David Stellwagen ,  Gil Moshe Lewitus

IPC分类号： A61K31/7028

CPC分类号： A61K31/7028 ,  A61P25/30 ,  A61P25/32 ,  A61P25/34 ,  A61P25/36 ,  Y02A50/473 ,  Y02A50/481

摘要： Methods of reducing AMPA/NMDA ratio in D1-type medium spiny neurons (MSN) and/or reducing development of behavioural sensitization or suppressing drug induced behavioural sensitization in a subject, optionally a subject that is afflicted with an addiction, the method comprising administering to the subject in need thereof an effective amount of a Toll-like receptor 4 (TLR4) agonist or a composition comprising said TLR4 agonist, preferably wherein the TLR4 agonist is a monophosphoryl lipid A (MPLA).

摘要翻译： 降低D1型中度多刺神经元（MSN）中AMPA / NMDA比例的方法和/或减少受试者（任选受瘾患病者）的行为敏化或抑制药物诱导的行为致敏的发展，所述方法包括给予 有需要的受试者有效量的Toll样受体4（TLR4）激动剂或包含所述TLR4激动剂的组合物，优选其中TLR4激动剂是单磷酰脂质A（MPLA）。

公开(公告)号：US20240350596A1

公开(公告)日：2024-10-24

申请号：US18685208

申请日：2022-08-24

申请人： University of Kentucky Research Foundation

发明人： Chang-Guo Zhan ,  Fang Zheng

IPC分类号： A61K38/46 ,  A61P25/30 ,  A61P25/34 ,  C12N9/18

CPC分类号： A61K38/465 ,  A61P25/30 ,  A61P25/34 ,  C12N9/18 ,  C12Y301/01008 ,  C07K2319/30

摘要： Compositions and methods for converting ghrelin to desacyl-ghrelin include a butyrylcholinesterase (BChE) polypeptide variant. The presently-disclosed subject matter includes compositions and methods for use in directly downregulating ghrelin. In particular, certain embodiments relate to compositions and methods for hydrolyzing/deacylating ghrelin to desacyl-ghrelin and applications thereof in the treatment of disorders involving ghrelin.